The safety problems that brought down Vioxx have tainted a whole class of drugs. Meredith Wadman examines their chances of a comeback.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Does administration of non-steroidal anti-inflammatory drug determine morphological changes in adrenal cortex: ultrastructural studies
Protoplasma Open Access 19 August 2010
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cannon, C. P. et al. Lancet 368, 1771–1781 (2006).
Xie, W. L., Chipman, J. G., Robertson, D. L., Erikson, R. L. & Simmons, D. L. Proc. Natl Acad. Sci. USA 88, 2692–2696 (1991).
McAdam, B. F. et al. Proc. Natl Acad. Sci. USA. 5, 272–277 (1999).
Catella-Lawson, F. et al. J. Pharmacol. Exp. Ther. 289, 735–741 (1999).
Related links
Related links
Related links in Nature Research
When good cholesterol turns bad
How does a painkiller harm the heart?
Review uncovers new killer drug
Related external links
Merck press release on FDA's Arcoxia rejection
Clinicaltrials.gov description of Pfizer-sponsored Celebrex/naproxen/ibuprofen trial
Analyst Seamus Fernandez of Leerink Swann
Novartis June 15 2007 press release on Prexige blood pressure effects
Rights and permissions
About this article
Cite this article
The pain game. Nature 448, 400–401 (2007). https://doi.org/10.1038/448400a
Published:
Issue Date:
DOI: https://doi.org/10.1038/448400a
